Mass spectrometry provides molecular, fragment, and elemental information with high sensitivity across organic, inorganic, biomolecular, and formulation samples.
This decision-focused guide explains the scientific measurement basis, when to use it, its limitations, sample amount considerations, competing methods, FDA-facing concerns, and common mistakes.
Mass spectrometry measures mass-to-charge ratios of ions. Coupled to LC or GC, it separates mixture components before detection; HRMS adds high-resolution accurate-mass data; MS/MS fragmentation supports structural hypotheses; ICP-MS supports trace elemental analysis.
Use MS for impurity ID, degradation products, extractables/leachables, metabolite or small-molecule characterization, polymer/additive work, trace-level detection, elemental impurities, and structure-elucidation support.
Ionization bias, matrix effects, adducts, in-source fragmentation, isomer ambiguity, poor chromatographic separation, and lack of authentic standards can limit certainty. MS often needs NMR, MicroED, chromatography, IR/Raman, or synthesis confirmation.
MS can be highly sensitive, but sample amount depends on concentration, ionization efficiency, matrix cleanup, replicate needs, and whether isolation is required. Trace analysis and structure ID should be scoped before assuming enough material exists.
NMR, chromatography with non-MS detectors, FTIR/Raman, MicroED, SCXRD, ICP/OES or XRF, and elemental analysis can compete or complement MS depending on the identity, quantitation, or structural question.
FDA cares about impurity identity, detection/quantitation limits, mass accuracy, specificity, validated sample prep, reference standards where needed, and whether the method supports the proposed control strategy under ICH Q2(R2)/Q14 and, for elements, ICH Q3D.
Common mistakes include reporting exact mass as a complete structure, ignoring adducts/isotopes, failing to prove coelution was resolved, over-assigning fragments, and not confirming clinically or toxicologically relevant impurities with orthogonal data.
Triclinic uses mass spectrometry to investigate unknowns, impurities, degradants, contaminants, extractables, leachables, and reaction or process-related components in real materials. Practical applications include assigning likely molecular formulas, comparing suspect peaks across lots or conditions, tracing degradation pathways, supporting impurity control strategies, and pairing accurate-mass data with orthogonal chemistry to reach defensible identifications.
The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this service area.
| Instrument or platform | Brand, model, software, or detector | Additional capabilities and use |
|---|---|---|
| MALDI-TOF MS | Voyager DE Pro MALDI | High-mass-range MALDI-TOF for polymers, lipids, oligosaccharides, phosphopeptides, proteins, and small molecules; molecular-weight and distribution support up to high mass ranges. |
| Triple quadrupole LC/MS/MS | Agilent 6460 Triple Quad LC/MS/MS | Trace-level detection and quantitative LC/MS/MS workflows for impurities, degradants, environmental, pharmaceutical, and clinical-style assays. |
| High-resolution accurate-mass LC/MS | Thermo Fisher Scientific Orbitrap Exploris 120 MS with Vanquish LC; quadrupole/ion-routing multipole/Orbitrap architecture; HCD and in-source fragmentation | High-resolution accurate-mass analysis with resolution up to 120,000 FWHM, UHPLC/LC workflows, unknown ID, formula constraints, and impurity/degradant characterization. |
| GC/MS | Thermo Fisher Scientific Thermo 8000 GC/MS; electron-impact ionization; DB-5 column and thermal-gradient operation | Volatile and semi-volatile component identification, residual-solvent support, and EI fragmentation/library-searchable spectra. |
| ICP-MS | Thermo Fisher Scientific iCAP RQ ICP-MS, single-quadrupole ICP-MS | Elemental and isotopic mass spectrometry for inorganic impurities, trace metals, and elemental quantitation. |
This example converts the legacy mass-spectrometry page's material-use discussion into a scoping table. Mass spectrometry can provide molecular, fragment, and elemental information with high sensitivity, but the right technique depends on the analyte, matrix, and decision. The table below shows how the same broad platform family can support different characterization questions.
| Material class | Mass-spectrometry use example |
|---|---|
| Small molecules, pharmaceuticals, and organic compounds | Molecular structure, purity, composition, degradation products, drugs, pesticides, pollutants, and synthetic chemicals. |
| Polymers and coatings | Molecular-weight distribution, polymer composition, cross-linking, degradation, additives, plasticizers, or impurities. |
| Biomolecules | Protein, peptide, lipid, nucleic-acid, and carbohydrate identification or quantitation using approaches such as MALDI-MS or LC-MS/MS. |
| Natural products | Molecular weights and structures of unknown compounds in complex natural-product mixtures, supplements, or plant extracts. |
| Metals and inorganic materials | Elemental and isotopic analysis using ICP-MS for metal alloys, nanomaterials, environmental samples, or geological materials. |
These examples include technical resources, regulatory guidances, or literature relevant to the technique. Download buttons are placed at the bottom-left of each example.
Author: Gary C. George III, Jason Vanlerberghe, and Stephan X.M. Boerrigter
Publication date: Q1 2026
Abstract: This Triclinic white paper explains a hybrid workflow in which HRMS provides accurate-mass/formula constraints and MicroED provides crystallographic structure evidence for trace impurities that may be difficult to isolate in amounts needed for traditional methods.
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: FDA notes that ICH Q2(R2) and Q14 describe validation and development principles for analytical procedures used to assess drug substance and drug product quality. These guidances frame FDA expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence.
Author: International Council for Harmonisation
Publication date: 2022
Abstract: ICH Q3D(R2) provides the risk-management framework for assessing and controlling elemental impurities in drug products. It is the regulatory anchor for elemental-impurity testing, method selection, and justification of ICP-MS, XRF, or other elemental-analysis strategies.
Use this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View technique
Tell Triclinic what sample you have, what decision the data must support, what prior data are available, and whether cGMP, release, validation, or regulatory documentation is required.
